Singhal, Rashi, Mitta, Sreedhar R., Das, Nupur K., Kerk, Samuel A., Sajjakulnukit, Peter, Solanki, Sumeet, Andren, Anthony, Kumar, Roshan, Olive, Kenneth P., Banerjee, Ruma, Lyssiotis, Costas A., and Shah, Yatrik M.
Hypoxia is a hallmark of solid tumors that promotes cell growth, survival, and metastasis and confers resistance to chemo and radiotherapies. Hypoxic responses are largely mediated by the transcription factors hypoxia-inducible factor 1[alpha] (HIF-1[alpha]) and HIF-2[alpha]. Our work demonstrates that HIF-2[alpha] is essential for colorectal cancer (CRC) progression. However, targeting hypoxic cells is difficult, and tumors rapidly acquire resistance to inhibitors of HIF-2[alpha]. To overcome this limitation, we performed a small molecule screen to identify HIF-2[alpha]-dependent vulnerabilities. Several known ferroptosis activators and dimethyl fumarate (DMF), a cell-permeable mitochondrial metabolite derivative, led to selective synthetic lethality in HIF-2[alpha]-expressing tumor enteroids. Our work demonstrated that HIF-2[alpha] integrated 2 independent forms of cell death via regulation of cellular iron and oxidation. First, activation of HIF-2[alpha] upregulated lipid and iron regulatory genes in CRC cells and colon tumors in mice and led to a ferroptosis-susceptible cell state. Second, via an iron-dependent, lipid peroxidation- independent pathway, HIF-2[alpha] activation potentiated ROS via irreversible cysteine oxidation and enhanced cell death. Inhibition or knockdown of HIF-2[alpha] decreased ROS and resistance to oxidative cell death in vitro and in vivo. Our results demonstrated a mechanistic vulnerability in cancer cells that were dependent on HIF-2[alpha] that can be leveraged for CRC treatment., Introduction Colorectal cancer (CRC) is the third most common cancer and one of the leading causes of cancer-related deaths globally (1, 2). Cancer cells expand rapidly, and all solid tumors [...]